(Circulation. 2000;101:e158.)
© 2000 American Heart Association, Inc.
Circulation Electronic Pages |
Factor XIII and Fibrinolytic Resistance
Professor of Clinical Chemistry Medical Clinic Nr I, R-3400 Cluj-Napoca, Romania, E-mail hemato@codec.ro
 |
Introduction |
|---|
 Top Introduction References |
|---|
To the Editor
Reed and Houng1 demonstrated that factor XIII-mediated cross-linking plays a critical role in limiting fibrinolysis in experimentally formed pulmonary emboli. They suggested that factor XIII could facilitate the growth of new or forming thrombi. This concept is supported by my observations, which began 26 years ago and emphasize increased plasma factor XIII levels in hypertriglyceridemic patients2 3 4 who also display high plasma fibronectin concentrations4 and an obviously prolonged dilute blood clot lysis time.5 Because the in vitro inhibition of factor XIII by p-chloromercuribenzoate led to an acceleration of clot lysis,5 I presumed that the association of high plasma factor XIII levels with impaired fibrinolysis was not merely casual. My colleagues and I also showed that platelet factor XIII is unlikely to make any significant contribution to plasma factor XIII levels.3 However, the significant correlations between liver-secreted serum cholinesterase and plasma factor XIII and fibronectin, as well as data obtained in patients with severely impaired hepatic protein synthesis (decompensated liver cirrhosis) or compensatively enhanced secretion of plasma proteins (nephrotic syndrome) provide circumstantial evidence that the liver is the main contributor to plasma factor XIII and fibronectin.4 Presumably, overloading the liver with lipids in a patient with insulin resistance would stimulate the synthesis of factor XIII, fibronectin, and serum cholinesterase. It is also reasonable to presume that thrombi richer in factor XIII and fibronectin would not only be more resistant to fibrinolysis but also more readily attached to the vessel wall. It is hoped that the convincing results reported by Reed and Houng1 will revive interest in pathologically increased factor XIII.
|
References |
|---|
|
TopIntroductionReferences |
|---|
1. Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation. 1999;99:299–304.
2. Cucuianu M, Vasile V, Popescu TA, Opincaru A, Crisnic I, Tapalaga D. Clinical studies concerning factor XIII: with special reference to hyperlipidemia. Thromb Diath Haemorrh. 1973;30:480–493.[Medline] [Order article via Infotrieve]
3. Cucuianu M, Miloshewski K, Porutiu D, Losowsky MS. Plasma factor XIII and platelet factor XIII in hyperlipaemia. Thromb Haemost. 1976;36:542–550.[Medline] [Order article via Infotrieve]
4. Cucuianu M, Rus HG, Cristea A, Niculescu F, Bedeleanu D, Porutiu D, Roman S. Clinical studies on plasma fibronectin and factor XIII: with special reference to hyperlipoproteinemia. Clin Chim Acta. 1985;147:273–281.[Medline] [Order article via Infotrieve]
5. Cucuianu M, Stef C, Zdrenghea D, Popescu O. In vitro effect of p-chlormercuribenzoate upon dilute blood clot lysis time in hyperlipemia. Thromb Haemost. 1979;42:929–944.[Medline] [Order article via Infotrieve]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||